Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: REGN

Regeneron Pharmaceuticals, Inc.

Healthcare | Biotechnology

Market prices for REGN are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$40.38

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:53 UTC.

What Regeneron Pharmaceuticals, Inc. does

Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. The company's product portfolio and product candidates in development are designed to address eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Summarized from Regeneron Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$40.38
Return on equity14.41%
Debt/equity0.06

Revenue, margins & earnings

FY2021 Net income: $8.08BFY2021 Taxes & interest: $872MFY2021 Operating costs: $7.12B$16.1BFY2021FY2022 Net income: $4.34BFY2022 Taxes & interest: $400MFY2022 Operating costs: $7.43B$12.2BFY2022FY2023 Net income: $3.95BFY2023 Operating costs: $9.07B$13.1BFY2023FY2024 Revenue: $14.2B — margin split not shown (non-operating gains)$14.2BFY2024FY2025 Revenue: $14.3B — margin split not shown (non-operating gains)$14.3BFY2025
  • Net income
  • Taxes & interest
  • Operating costs
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-15
  • 2026-10-15Co-Chief Scientific OfficerSale-50$39.1K
  • 2026-10-15Co-Chief Scientific OfficerOption exercise17,000$6.49M
  • 2026-10-15Co-Chief Scientific OfficerSale-25$19.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Regeneron Pharmaceuticals, Inc. do?

Regeneron Pharmaceuticals is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases.

When did REGN last file with the SEC?

Regeneron Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-06. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:53 UTC. This page is also available as JSON at /api/data?ticker=REGN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for REGN and 5,000+ tickers.

Create a free account — keep REGN
For your agent
GET /api/data?ticker=REGN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt